UK 2026: One IPO, Manual Updates and How They Change Biotech Patent Drafting & International Filing

Key summary: The UKIPO’s One IPO patent service, launched Spring 2026, removes the built-in facility for filing PCT applications. From 1 January 2026, UK applicants must use WIPO ePCT, the EPO as Receiving Office, or authorised agents to file international patent applications. Coupled with a roughly 25 % fee rise effective 1 April 2026 and tightened Manual of Patent Practice guidance on plausibility and sufficiency for biological inventions, these UK patent filing changes demand immediate action from every biotech patent team.

The confluence of three regulatory shifts, new filing mechanics, higher costs, and stricter examination standards, means that biotech and pharmaceutical companies cannot simply port legacy workflows into the new system. Claim drafting templates, biological disclosure practices (sequence listings, deposits, plausibility evidence) and international filing route choices all require revision. This guide provides the practical, life-sciences-specific playbook that in-house counsel, chief patent counsels and R&D leaders need to navigate these UKIPO 2026 changes confidently.

• Within 30 days: Confirm WIPO ePCT account access and digital signature capability for all designated filing agents; audit pending PCT applications for transition readiness.
• Within 60 days: Revise specification and claim templates to address updated plausibility and enablement expectations in the Manual of Patent Practice.
• Within 90 days: Complete a portfolio-wide cost audit using the new 1 April 2026 fee schedule and select optimal filing routes (PCT via ePCT, direct EP, or UK national) for each active programme.

What Changed in 2026, One IPO, Fee Changes and Manual of Patent Practice Updates

The UK patent filing changes that took effect across 2025–2026 arrived in three distinct waves. On 21 October 2025, the UK Intellectual Property Office published its official notice on changes to international patent filing, confirming that the new One IPO patent service would not include a built-in PCT filing facility. From 1 January 2026, the practical mechanics of PCT filing from the UK shifted to external platforms. The One IPO patent service itself launched in Spring 2026, replacing legacy filing interfaces with a streamlined, but narrower, digital service focused on UK national prosecution. Finally, on 1 April 2026, new fee schedules took effect under the GOV.

UK publication on intellectual property office fees, increasing charges for patents, trade marks and designs by approximately 25 %.

In parallel, the Manual of Patent Practice received updates that sharpen examination standards for biological inventions. These manual of patent practice updates reinforce the requirement that claims, particularly broad functional claims common in antibody and vaccine patent applications, must be supported by evidence of plausibility at the filing date. The updates also clarify expectations around sufficiency of disclosure for inventions involving nucleotide and amino acid sequences, aligning more closely with developing EPO case law on the same issues.

How One IPO Changes PCT/EP/UK Filing Mechanics, Practical Filing Routes and Workflows

The most immediately disruptive of the UK patent filing changes is the removal of integrated PCT filing from the UKIPO’s digital service. Before 2026, applicants filing through the UK IPO could submit a PCT application with the UKIPO acting as the Receiving Office in a single workflow. The One IPO patent service does not replicate this capability. As detailed in the UKIPO’s official blog post, applicants now have four principal routes for PCT filing from the UK.

Understanding the practical differences between these routes is essential for biotech patent drafting workflows, because each imposes different requirements for document formatting, sequence listing uploads, digital signatures and fee payment timing.

For biotech teams managing portfolios with both UK national and international filings, industry observers expect the dominant workflow to become a dual-track approach: file UK nationals through One IPO and file PCTs concurrently through WIPO ePCT. Teams that have not yet established ePCT accounts and tested ST.26 sequence listing uploads should treat this as an urgent administrative priority.

Cost and Timing Analysis, Fee Impact and Portfolio Tactics After the 1 April 2026 Fee Rise

The new fees published by GOV.UK effective 1 April 2026 represent one of the largest single-year increases in UKIPO history. For a typical biotech filing programme that includes national filings, search requests, examination fees and renewal payments, the cumulative impact is substantial. The fee increase applies to all patent-related actions at the UKIPO, meaning that it affects initial filings, requests for examination, and every annual renewal in the portfolio.

Practical tactics for controlling costs include: filing renewals before the 1 April 2026 cut-off where deadlines permit; consolidating divisional filings to reduce duplicated fees; and, for programmes with a primarily European focus, assessing whether direct EP filing with later UK validation is more cost-effective than a parallel UK national filing. These decisions should be made programme-by-programme, factoring in prosecution timeline, commercial launch date and freedom-to-operate needs.

Biotech Patent Drafting Implications, Enablement, Plausibility and Evidence

Beyond filing mechanics and fees, the most consequential of the UKIPO 2026 changes for life-sciences applicants are the tightened plausibility and sufficiency standards reflected in the Manual of Patent Practice updates. These updates bring UK examination practice closer to the approach articulated in recent EPO Enlarged Board of Appeal decisions, particularly regarding the evidence required at the filing date to make broad claims plausible.

For biotech patent drafting, this means that the specification must, at the date of filing, provide sufficient evidence, whether experimental data, structural characterisation, or clear mechanistic reasoning, to make it plausible that the invention works across the full scope of the claims. A specification that describes one monoclonal antibody binding to a target but claims all antibodies that bind to that target will face heightened scrutiny. The same principle applies to vaccine compositions, therapeutic proteins and diagnostic methods.

A critical nuance under the Patents Act 1977 is the exclusion of methods of diagnosis practised on the human or animal body. Diagnostic claims must be drafted as in vitro methods using a sample obtained from the body, not as diagnostic methods applied to a patient. This exclusion, set out in the statute and reinforced in the Manual of Patent Practice, remains a common trap for applicants porting claim sets drafted for US prosecution into the UK.

Claim Drafting for UK Patent Filing Changes: Antibodies, Vaccines and Protein Therapeutics, Examples and Red Flags

The practical implications of tightened plausibility standards become clearest when examined through concrete antibody patent claims. Below are illustrative examples showing progressively stronger claim structures, together with the prosecution risks each presents under current UKIPO and EPO practice.

Antibody Claim Examples

Example 1, Broad functional claim (high risk): “An isolated antibody that specifically binds to protein X and inhibits its biological activity.” This claim defines the antibody entirely by function. Under the manual of patent practice updates, an examiner will likely raise a plausibility objection unless the specification discloses multiple structurally distinct antibodies achieving this function, supported by binding and inhibition data.

Example 2, Hybrid structural-functional claim (moderate risk): “An isolated antibody comprising a heavy chain variable region comprising CDR-H1 of SEQ ID NO: 2, CDR-H2 of SEQ ID NO: 3 and CDR-H3 of SEQ ID NO: 4, which antibody specifically binds to protein X with a K_D of 10 nM or less.” This claim anchors the antibody structurally via CDR sequences while retaining a functional limitation. Prosecution risk is moderate, the specification should include binding affinity data for at least the exemplified antibody and preferably for variants with conservative CDR substitutions.

Example 3, Sequence-defined claim (lower risk): “An isolated antibody comprising a VH domain of SEQ ID NO: 5 and a VL domain of SEQ ID NO: 6.” Narrow scope but robust defensibility. This approach is recommended for lead clinical candidates where broad genus protection is not supported by the filing-date data set. Dependent claims can layer in functional properties, formulation contexts and therapeutic applications.

Vaccine and Therapeutic Protein Examples

Vaccine claim example: “An immunogenic composition comprising a polypeptide having at least 90 % sequence identity to SEQ ID NO: 10, together with a pharmaceutically acceptable adjuvant.” The “at least 90 %” identity threshold must be supported by disclosure showing that variants within this range retain immunogenicity. Including an alignment table and immunogenicity data for at least two variants within the claimed range significantly strengthens the position during EPO prosecution 2026 standards and UK examination alike.

Therapeutic protein claim example: “A fusion protein comprising a first domain having the amino acid sequence of SEQ ID NO: 12 linked to an Fc region of a human IgG1, for use in the treatment of inflammatory bowel disease.” The “for use in” formulation is the standard European second-medical-use claim format and is accepted in UK prosecution. Ensure the specification includes at least in vitro or animal model data demonstrating anti-inflammatory efficacy.

Diagnostics and Biomarkers

Diagnostic claim example: “An in vitro method for detecting susceptibility to condition Y in a biological sample obtained from a subject, comprising measuring the level of biomarker Z using an antibody that specifically binds to SEQ ID NO: 15, wherein a level above threshold T indicates susceptibility.” The in vitro framing avoids the diagnostic method exclusion under the Patents Act 1977. The claim defines both the biomarker (by sequence) and the threshold (quantitatively), reducing the risk of insufficiency objections.

Biological Sequence Listings, ST.26, Deposits and Data Formats

Biological sequence listings remain a mandatory component of any patent application disclosing nucleotide or amino acid sequences of 10 or more specifically defined nucleotides or 4 or more specifically defined amino acids. The WIPO ST.26 XML standard is the required format for PCT, EP and UK national filings. Compliance errors in sequence listings are among the most common formality deficiencies flagged by receiving offices and can delay filing dates.

Where the invention involves a biological material that cannot be adequately described in writing, for example, a specific hybridoma cell line producing a monoclonal antibody, deposit under the Budapest Treaty at a recognised International Depositary Authority (IDA) remains the appropriate strategy. The deposit must be made before or on the filing date, and the accession number must be included in the specification. This requirement is unchanged by the One IPO transition but merits re-emphasis given the tightened plausibility landscape.

Cross-Jurisdiction Prosecution Tactics, EPO vs UK Prosecution Differences in 2026

With EPO prosecution 2026 guidelines also tightening standards for biotechnological inventions, particularly around plausibility in the wake of Enlarged Board decision G 2/21, biotech applicants face converging but not identical examination regimes in the UK and at the EPO. Understanding the remaining differences is critical for drafting claims that survive prosecution in both forums without requiring costly divisional strategies.

A practical recommendation is to draft claims with a single unified claim set optimised for EPO prosecution (which tends to apply stricter added-matter and clarity standards), then adapt for UK national filing only where specific UK claim formatting or scope advantages exist. This minimises drafting divergence and reduces the cost of maintaining parallel prosecutions. For programmes where UK-first grant is strategically important, for example, to support a UK regulatory submission or litigation position, the UKIPO’s accelerated examination service can deliver a granted patent significantly faster than the EPO timeline.

Quick-Action Checklist for the Next 30–90 Days

The following prioritised checklist translates the UK patent filing changes discussed above into concrete steps for in-house biotech IP teams.

• Days 1–30: Filing infrastructure. Verify that all designated patent attorneys and filing agents have active WIPO ePCT accounts with valid digital certificates. Test a dummy filing to confirm ST.26 sequence listing upload functionality. Confirm EPO Online Filing access as a backup Receiving Office route.
• Days 1–30: Budget revision. Obtain the complete new UKIPO fee schedule effective 1 April 2026. Re-forecast annual portfolio costs, including renewals, examination fees and any pending divisional filings. Identify any renewals or procedural actions that can be completed before the fee increase takes effect.
• Days 30–60: Specification and claim template review. Audit current biotech specification templates against the updated Manual of Patent Practice plausibility and sufficiency guidance. Ensure all templates include prompts for: (a) exemplified data matching claim scope, (b) ST.26-compliant sequence listing references, (c) Budapest Treaty deposit accession numbers where applicable, and (d) in vitro framing for diagnostic claims.
• Days 30–60: Pending application audit. Review all pending UK and PCT applications with biotech subject matter. Flag claims that rely solely on functional definitions without structural anchors. Prepare voluntary amendment strategies for applications at risk of plausibility objections under the updated guidance.
• Days 60–90: Filing route optimisation. For each active R&D programme, map the optimal international filing route (PCT via ePCT, direct EP, UK national, or combination) based on target markets, prosecution timeline needs and the new fee landscape. Document the decision rationale for each programme.
• Days 60–90: External counsel briefing. Brief all external patent attorneys on the updated internal workflows, including the shift to ePCT for PCT filings and any revised claim drafting standards. Confirm that external counsel have validated their own ePCT and EPO filing capabilities.

Conclusion

The 2026 UK patent filing changes, One IPO’s streamlined but narrower service, the shift to ePCT for international filings, a substantial fee rise, and stricter plausibility standards, collectively require biotech IP teams to update every stage of their filing and prosecution workflow. From claim drafting that anchors scope to structural features and exemplified data, through ST. 26-compliant biological sequence listings, to a deliberate choice between PCT, EP and UK national routes, the decisions made now will determine prosecution outcomes for years to come. Teams that adapt early will secure stronger patents at lower cost; those that delay risk objections, missed deadlines and budget overruns.

Consult a qualified patent lawyer in the United Kingdom or explore the UK patent practice area to obtain advice tailored to your portfolio.

Sources

1. UK Intellectual Property Office, “What’s changing – filing international patents”
2. GOV.UK, Apply for a patent
3. GOV.UK, New fees from 1 April 2026 for designs, trade marks and patents
4. WIPO, PCT Applicant’s Guide (United Kingdom)
5. Patents Act 1977 (legislation.gov.uk)
6. UKIPO Manual of Patent Practice
7. European Patent Office, Guidelines for Examination